ORTINLAB Stock Overview
Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Ortin Laboratories Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹20.00 |
52 Week High | ₹30.35 |
52 Week Low | ₹16.20 |
Beta | 1.27 |
1 Month Change | 13.96% |
3 Month Change | -6.54% |
1 Year Change | 2.56% |
3 Year Change | -30.56% |
5 Year Change | -27.55% |
Change since IPO | -26.44% |
Recent News & Updates
Recent updates
Here's Why I Think Ortin Laboratories (NSE:ORTINLABSS) Might Deserve Your Attention Today
Jan 24Is Ortin Laboratories (NSE:ORTINLABSS) A Risky Investment?
Dec 27Ortin Laboratories Limited (NSE:ORTINLABSS) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Nov 30Here's Why Ortin Laboratories (NSE:ORTINLABSS) Is Weighed Down By Its Debt Load
Sep 15Shareholder Returns
ORTINLAB | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 4.2% | 2.3% | 2.6% |
1Y | 2.6% | 56.7% | 45.0% |
Return vs Industry: ORTINLAB underperformed the Indian Pharmaceuticals industry which returned 56.7% over the past year.
Return vs Market: ORTINLAB underperformed the Indian Market which returned 45% over the past year.
Price Volatility
ORTINLAB volatility | |
---|---|
ORTINLAB Average Weekly Movement | 6.2% |
Pharmaceuticals Industry Average Movement | 6.0% |
Market Average Movement | 6.8% |
10% most volatile stocks in IN Market | 10.0% |
10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: ORTINLAB has not had significant price volatility in the past 3 months.
Volatility Over Time: ORTINLAB's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1986 | 24 | Sanka Murali Murthy | www.ortinlabsindia.com |
Ortin Laboratories Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders. It provides formulations, such as anti-diabetics, anti allergics, sedatives and tranquilisers, anti helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides; and anti-anginal and cardio vascular, and antifungal products.
Ortin Laboratories Limited Fundamentals Summary
ORTINLAB fundamental statistics | |
---|---|
Market cap | ₹161.49m |
Earnings (TTM) | -₹41.00m |
Revenue (TTM) | ₹34.23m |
4.7x
P/S Ratio-3.9x
P/E RatioIs ORTINLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ORTINLAB income statement (TTM) | |
---|---|
Revenue | ₹34.23m |
Cost of Revenue | ₹45.58m |
Gross Profit | -₹11.34m |
Other Expenses | ₹29.65m |
Earnings | -₹41.00m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.04 |
Gross Margin | -33.14% |
Net Profit Margin | -119.76% |
Debt/Equity Ratio | 61.6% |
How did ORTINLAB perform over the long term?
See historical performance and comparison